title: [Monitoring and precautions to take during treatment with a biological immunomodulator].
authors.affiliation: Service de rhumatologie, Centre national de références des maladies auto-immunes systémiques, hôpital de Hautepierre, CHU de Strasbourg, avenue Molière, 67098 Strasbourg cedex, France. Jean.Sibilia@chru-strasbourg.fr
authors.forename: J
authors.initials: J
authors.lastname: Sibilia
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001691:Biological Therapy / Q000009:adverse effects / Q000379:methods; D000075202:Contraindications; D016903:Drug Monitoring / Q000379:methods; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018570:Risk Assessment; D012307:Risk Factors; D000069283:Rituximab; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D014409:Tumor Necrosis Factor-alpha; D000069283:Rituximab
vernacular_title: Surveillance et précautions à prendre lors d'un traitement par un immunomodulateur biologique.